We are monitoring the impact of COVID-19 on Europe Biologics Market Get in touch with us for detailed analysis Know More
Pulished Date May, 2021
ID: 11529
Share on
Share on

Europe Biologics Market Research Report – Segmented By Source, Product, Biologics Manufacturing Type, Disease Category and Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) – Industry Size, Share, Trends, Growth & Forecast (2021 to 2026)

Pulished: May, 2021
ID: 11529
Pages: 100

Europe Biologics Market Size (2021 to 2026)

The size of the European biologics market is forecasted to witness a healthy CAGR during the forecast period.

Biologics, which are used to treat various illnesses and conditions, including anemia, cancers, and autoimmune diseases, are expected to fuel the European biologics market growth. Also, increasing demand for innovative therapies, Y-O-Y rise in the prevalence of chronic diseases in this region, and drastic changes in people's social behavior are expected to drive the market growth. Furthermore, a better understanding of the genetic and molecular origin of disease has paved the way for advancing a variety of tailored therapies. Recombinant proteins, for example, assist the immune system in identifying and binding foreign molecules.

Besides, increasing capital investment from critical players and growing population is most likely to propel the market growth. Furthermore, Robust advancements in research and development activities and emerging markets are expected to increase the biologics market growth. Biomedical science relies heavily on gene-based and cellular biologics, which are used to treat various medical conditions, including rare diseases. Because of their massive molecular scale and delicate molecular composition, biologic drugs are normally injected into the patient's body. Market growth is expected to be fueled by population growth and improvements in social behavior. The biopharmaceutical contract manufacturing market is developing majorly due to the accelerating demand for biologics and growing outsourcing by the pharmaceutical companies in developed countries such as Germany, UK, and France in the European region. 

Pricing pressures from regulators and a lack of knowledge about biosimilars among primary care physicians and specialists were two factors that hampered growth in the past. Also, the lower availability of biologics in lower-income countries is expected to hamper the market growth. On the other hand, high cost and lack of reimbursement for biologics impede the Biologics market in Europe.

Impact of COVID-19 on the European Biologics Market:

During the pandemic lockdown, the biologics market in Europe was disrupted, and biologics consumer devices and prescription drug production were delayed. Due to the strict COVID-19 rules, no biologics drugs have been extracted during the first quarter of 2020. The rising COVID-19 burden has generated a huge demand for biologics during the pandemic, propelling the market further. The COVID-19 pandemic has created a positive impact on the European biologics market during the pandemic period. 

The manufacturers have performed biologics safety testing to detect viruses, Mycoplasma, and bacterial toxins. The market has experienced specific growth. According to World Health Organization (WHO), by 2020, chronic diseases would develop cardiovascular disease (CVD) cause 3.9 million deaths in Europe Cancer, autoimmune diseases, and over 1.8 million deaths in the EU overall biologics market.

 For example, the National Research Council of Canada and CanSino Biologics, based in China, partnered in May 2020 on the clinical production of a COVID-19 vaccine in Canada. Ad5-nCoV is an adenovirus Type 5 vector-based vaccine currently in Phase II production in Wuhan, China. As a result, comprehensive research and development activities on biologics for the treatment of COVID-19 are expected to fuel the biologics market's expansion.

This research report on the European Biologics Market has been segmented & sub-segmented into the following categories:

By Source:  

  • Microbial
  • Mammalian
  • Others

By Product:

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Proteins
  • Antisense, RNAi, & Molecular Therapy
  • Others

By Biologics Manufacturing:

  • Outsourced
  • In-house

By Disease Category:

  • Oncology
  • Infectious Diseases
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, the European biologics market is projected to witness significant growth heights during the forecast period. The growth is attributed to the market's continuing expansion of its product range and the growing market for biologics around Europe. The growing prevalence of chronic diseases, continuing research and development, and ongoing investment in biologics all add to the market's overall growth. The European population is aging, with one-fifth of the overall EU population over the age of 65. 

The German biologics market is forecasted to account leading share in the European market during the forecast period. A major rise in the burden of lifestyle diseases has occurred in the country. Diabetes, infectious disorders, oncology, and other diseases have been on the rise in Germany, and this is expected to fuel market development in the coming years.

The UK biologics market is expected to be another lucrative regional market in the European region and expected to have a healthy growth rate during the forecast period. Due to the increasing number of biologics medication approvals by regulatory authorities, the UK is expected to maintain a leading place in the global biologics market over the projected period.

KEY MARKET PLAYERS:

Notable companies operating in the European biologics market analyzed in this report are Johnson & Johnson (J&J), F Hoffmann-La Roche, Bristol-Myers Squibb, GlaxoSmithKline, AbbVie, Amgen, Sanofi, Eli Lilly and Company, Merck & Co., and Pfizer Inc.

  1. Introduction
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year and Forecast Periods
    4. General Study Assumptions
  2. Research Methodology
    1. Introduction
    2. Research Phases
        1. Secondary Research
        2. Primary Research
        3. Econometric Modelling
        4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. Overview
    1. Executive Summary
    2. Key Inferences
    3. New Developments
  4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
    1. Market Drivers
    2. Market Restraints
    3. Key Challenges
    4. Current Opportunities in the Market
  5. Market Segmentation
    1. By Source
      1. Microbial
      2. Mammalian
      3. Others
    2. By Product
      1. Monoclonal Antibodies
      2. Vaccines
      3. Recombinant Proteins
      4. Antisense, RNAi, & Molecular Therapy
      5. Others
    3. By Biologics Manufacturing
      1. Outsourced
      2. In-house
    4. By Disease Category
      1. Oncology
      2. Infectious Diseases
      3. Immunological Disorders
      4. Cardiovascular Disorders
      5. Hematological Disorders
      6. Others
  6. Geographical Analysis
    1. Introduction    
      1. Regional Trends   
      2. Impact Analysis    
      3. Y-o-Y Growth Analysis        
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
      4. Market Attractiveness Analysis      
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
      5.      Market Share Analysis   
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
    2. Europe
      1. Introduction
      2. UK
      3. France
      4. Spain
      5. Germany
      6. Italy
  7. Strategic Analysis
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. Threat of New Entrants
      4. Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  8. Market Leaders' Analysis
    1. Johnson & Johnson (J&J)
      1. Overview
      2. Product Analysis
      3. Strategic Evaluation and Operations
      4. Financial analysis
      5. Legal issues
      6. Recent Developments
      7. SWOT analysis
      8. Analyst View
    2. F Hoffmann-La Roche
    3. Bristol-Myers Squibb
    4. GlaxoSmithKline
    5. AbbVie
    6. Amgen
    7. Sanofi
    8. Eli Lilly and Company
    9. Merck & Co.
    10. Pfizer
  9. Competitive Landscape
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, Collaborations and Joint Ventures
    4. New Product Launches
  10. Market Outlook and Investment Opportunities
  11. Appendix
    1. List of Tables
    2. List of Figures  
  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail.
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development.
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment.
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies.
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions.
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market.
  1. Europe Biologics Market, By Source, From 2021 to 2026 (USD Million)
  2. Europe Microbial Market, By Region, From 2021 to 2026 (USD Million)
  3. Europe Mammalian Market, By Region, From 2021 to 2026 (USD Million)
  4. Europe Others Market, By Region, From 2021 to 2026 (USD Million)
  5. Europe Biologics Market, By Product, From 2021 to 2026 (USD Million)
  6. Europe Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  7. Europe Vaccines Market, By Region, From 2021 to 2026 (USD Million)
  8. Europe Recombinant Proteins Market, By Region, From 2021 to 2026 (USD Million)
  9. Europe Antisense, RNAi, & Molecular Therapy Market, By Region, From 2021 to 2026 (USD Million)
  10. Europe Others Market, By Region, From 2021 to 2026 (USD Million)
  11. Europe Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Million)
  12. Europe Outsourced Market, By Region, From 2021 to 2026 (USD Million)
  13. Europe In-house Market, By Region, From 2021 to 2026 (USD Million)
  14. Europe Biologics Market, By Disease Category, From 2021 to 2026 (USD Million)
  15. Europe Oncology Market, By Region, From 2021 to 2026 (USD Million)
  16. Europe Infectious Diseases Market, By Region, From 2021 to 2026 (USD Million)
  17. Europe Immunological Disorders Market, By Region, From 2021 to 2026 (USD Million)
  18. Europe Cardiovascular Disorders Market, By Region, From 2021 to 2026 (USD Million)
  19. Europe Hematological Disorders Market, By Region, From 2021 to 2026 (USD Million)
  20. Europe Others Market, By Region, From 2021 to 2026 (USD Million)
  21. U.K. Biologics Market, By Source, From 2021 to 2026 (USD Million)
  22. U.K. Biologics Market, By Product, From 2021 to 2026 (USD Million)
  23. U.K. Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Million)
  24. U.K. Biologics Market, By Disease Category, From 2021 to 2026 (USD Million)
  25. Germany Biologics Market, By Source, From 2021 to 2026 (USD Million)
  26. Germany Biologics Market, By Product, From 2021 to 2026 (USD Million)
  27. Germany Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Million)
  28. Germany Biologics Market, By Disease Category, From 2021 to 2026 (USD Million)
  29. France Biologics Market, By Source, From 2021 to 2026 (USD Million)
  30. France Biologics Market, By Product, From 2021 to 2026 (USD Million)
  31. France Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Million)
  32. France Biologics Market, By Disease Category, From 2021 to 2026 (USD Million)
  33. Italy Biologics Market, By Source, From 2021 to 2026 (USD Million)
  34. Italy Biologics Market, By Product, From 2021 to 2026 (USD Million)
  35. Italy Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Million)
  36. Italy Biologics Market, By Disease Category, From 2021 to 2026 (USD Million)
  37. Spain Biologics Market, By Source, From 2021 to 2026 (USD Million)
  38. Spain Biologics Market, By Product, From 2021 to 2026 (USD Million)
  39. Spain Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Million)
  40. Spain Biologics Market, By Disease Category, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample